I hold Avita and have seen how much the market slams companies when it looks like revenue growth is struggling to deal with cost escalation. And if the market sniffs a near term CR then the SP gets crushed. That said it wouldn't be hard to find some still a way off profitability and with revenue not much higher than Eye but much bigger market caps. At $51 million and around a PS ratio of 2 I can only call this undervalued. That only makes sense though if you're playing a longer game which is my situation.
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-273
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.005(3.33%) |
Mkt cap ! $35.50M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.5¢ | 15.5¢ | $13.41K | 86.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 581087 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 150000 | 2 |
View Market Depth
| Last trade - 13.10pm 15/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |